Gregory J Keir

List of Publications by Year
in descending order

21 papers	1,315 citations	687363 13 h-index	794594 19 g-index
21 all docs	21 docs citations	21 times ranked	1429 citing authors

#	Article	IF	Citations
1	Direct oral anticoagulants for cancerâ€associated venous thromboembolisms: a systematic review and network metaâ€analysis. Internal Medicine Journal, 2022, 52, 272-281.	0.8	14
2	Unravelling the enigma of <scp>systemic lupus erythematosus</scp>â€associated <scp>ILD</scp>. Respirology, 2022, 27, 567-568.	2.3	0
3	Diagnosis and management of connective tissue diseaseâ€associated interstitial lung disease in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand*. Respirology, 2021, 26, 23-51.	2.3	45
4	Thrombolysis for massive pulmonary embolisms in morbid obesity: a multisite caseâ€“control study. ERJ Open Research, 2021, 7, 00762-2020.	2.6	0
5	Use of direct oral anticoagulants for acute pulmonary embolisms in obesity: a propensity-matched, multicentre caseâ€“control study. ERJ Open Research, 2021, 7, 00379-2021.	2.6	1
6	Peer Connect Service for people with pulmonary fibrosis in Australia: Participants' experiences and process evaluation. Respirology, 2020, 25, 1053-1059.	2.3	13
7	Eligibility for antiâ€fibrotic treatment in idiopathic pulmonary fibrosis depends on the predictive equation used for pulmonary function testing. Respirology, 2019, 24, 988-995.	2.3	7
8	Pulmonary hypertension in interstitial lung disease: Limitations of echocardiography compared to cardiac catheterization. Respirology, 2018, 23, 687-694.	2.3	39
9	Diagnosis and management of idiopathic pulmonary fibrosis: Thoracic Society of Australia and New Zealand and Lung Foundation Australia position statements summary. Medical Journal of Australia, 2018, 208, 82-88.	1.7	13
10	Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry. BMC Pulmonary Medicine, 2018, 18, 19.	2.0	58
11	A stepwise composite echocardiographic score predicts severe pulmonary hypertension in patients with interstitial lung disease. ERJ Open Research, 2018, 4, 00124-2017.	2.6	16
12	Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. European Respiratory Journal, 2017, 49, 1601592.	6.7	174
13	Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial. Trials, 2017, 18, 275.	1.6	121
14	Treatment of idiopathic pulmonary fibrosis in <scp>A</scp>ustralia and <scp>N</scp>ew Zealand: <scp>A</scp> position statement from the <scp>T</scp>horacic <scp>S</scp>ociety of <scp>A</scp>ustralia and <scp>N</scp>ew <scp>Z</scp>ealand and the <scp>L</scp>ung <scp>F</scp>oundation <scp>A</scp>ustralia. Respirology, 2017, 22, 1436-1458.	2.3	39
15	Pulmonary Vasospasm in Systemic Sclerosis: Noninvasive Techniques for Detection. Pulmonary Circulation, 2015, 5, 498-505.	1.7	2
16	Cyclical caspofungin for chronic pulmonary aspergillosis in sarcoidosis. Thorax, 2014, 69, 287-288.	5.6	28
17	Connective tissue disease related fibrotic lung disease: high resolution computed tomographic and pulmonary function indices as prognostic determinants. Thorax, 2014, 69, 216-222.	5.6	176
18	Rituximab in severe, treatmentâ€refractory interstitial lung disease. Respirology, 2014, 19, 353-359.	2.3	217

#	Article	IF	Citations
19	An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study. Lancet Respiratory Medicine,the, 2014, 2, 123-130.	10.7	178
20	Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. European Respiratory Journal, 2012, 40, 641-648.	6.7	123
21	Assessing Pulmonary Disease and Response to Therapy: Which Test?. Seminars in Respiratory and Critical Care Medicine, 2010, 31, 409-418.	2.1	51